Genmab A/S
GMAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $21,526 | $16,474 | $14,505 | $8,417 |
| % Growth | 30.7% | 13.6% | 72.3% | – |
| Cost of Goods Sold | $985 | $226 | $0 | $0 |
| Gross Profit | $20,541 | $16,248 | $14,505 | $8,417 |
| % Margin | 95.4% | 98.6% | 100% | 100% |
| R&D Expenses | $9,748 | $7,630 | $5,562 | $4,181 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3,790 | $3,297 | $2,676 | $1,283 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $300 | $0 | $0 | $0 |
| Operating Expenses | $13,838 | $10,927 | $8,238 | $5,464 |
| Operating Income | $6,703 | $5,321 | $6,267 | $2,953 |
| % Margin | 31.1% | 32.3% | 43.2% | 35.1% |
| Other Income/Exp. Net | $2,461 | $316 | $678 | $965 |
| Pre-Tax Income | $9,164 | $5,637 | $6,945 | $3,918 |
| Tax Expense | $1,320 | $1,285 | $1,493 | $961 |
| Net Income | $7,844 | $4,352 | $5,452 | $2,957 |
| % Margin | 36.4% | 26.4% | 37.6% | 35.1% |
| EPS | 12.14 | 6.6 | 8.34 | 4.52 |
| % Growth | 83.9% | -20.9% | 84.5% | – |
| EPS Diluted | 12.14 | 6.6 | 8.26 | 4.48 |
| Weighted Avg Shares Out | 646 | 659 | 654 | 654 |
| Weighted Avg Shares Out Dil | 646 | 659 | 660 | 660 |
| Supplemental Information | – | – | – | – |
| Interest Income | $995 | $939 | $324 | $197 |
| Interest Expense | $120 | $27 | $21 | $13 |
| Depreciation & Amortization | $413 | $240 | $362 | $250 |
| EBITDA | $9,697 | $5,947 | $7,346 | $4,181 |
| % Margin | 45% | 36.1% | 50.6% | 49.7% |